白蛋白市场规模、份额和成长分析（按类型、应用、销售管道、最终用户和地区）- 2025-2032 年产业预测

2023 年白蛋白市场规模价值为 66.9 亿美元，预计将从 2024 年的 70.8 亿美元成长到 2032 年的 112.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.9%。

全球白蛋白市场预计将显着成长，因为它具有增加血液容量、治疗肝病和治疗烧烫伤等重要的医疗应用。白蛋白的主要功能是维持渗透压和运输必需物质，增强了其治疗潜力。驱动因素包括危及生命的疾病盛行率上升、外科手术数量增加（2022 年全球将进行 3.1 亿例手术）以及非治疗用途的增加。 Grifols 对熊果素治疗肝硬化的评估，以及 Shilpa Biologicals 的环境友善重组人体血清蛋白等创新进展标誌着人们正向更有效、更永续的产品转变。 AlvMedics 和 Valneva 等公司在改进疫苗配方方面的合作表明了该行业对推进医疗保健解决方案和增加全球获得基本治疗机会的承诺。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局

白蛋白市场规模（按类型）

• 市场概况
• 人血清白蛋白
• 牛血清白蛋白
• 重组白蛋白

白蛋白市场规模（按应用）

• 市场概况
• 治疗
• 药物处方和疫苗
• 媒体元件
• 其他用途

白蛋白市场规模（依销售管道）

• 市场概况
• 企业对消费者 (B2C)
• 企业对企业 (B2B)

白蛋白市场规模（依最终用户划分）

• 市场概况
• 医院和诊所
• 製药和生物技术公司
• 研究组织

白蛋白市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Merck KGaA（Germany）
• CSL Limited（Australia）
• Grifols SA（Spain）
• Baxter International Inc.（USA）
• China Biologic Products Holdings, Inc.（China）
• Takeda Pharmaceuticals（Japan）
• Octapharma AG（Switzerland）
• Novozymes A/S（Denmark）
• Thermo Fisher Scientific Inc.（USA）
• Ventria Bioscience（USA）
• Albumedix Ltd.（UK）
• Biotest AG（Germany）
• HiMedia Laboratories（India）
• Invitria（USA）
• Medxbio Pte Ltd.（Singapore）
• RayBiotech, Inc.（USA）
• SeraCare（USA）
• Kedrion SpA（Italy）
• Albumin Therapeutics, LLC（USA）

结论和建议

Albumin Market size was valued at USD 6.69 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 11.21 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The global albumin market is poised for significant growth due to its critical medical applications in increasing blood volume, treating liver diseases, and managing burn injuries. Key functions of albumin, such as maintaining osmotic pressure and transporting essential substances, enhance its therapeutic potential. Driving factors include the rising prevalence of life-threatening diseases, an increase in surgical procedures-310 million surgeries were performed globally in 2022-and an uptick in non-therapeutic uses. Innovative advancements, like Grifols' evaluation of Albutein for cirrhosis, and Shilpa Biologicals' environmentally friendly recombinant Human Albumin, signal a shift towards more effective and sustainable products. Collaborations, like that of Albumedix with Valneva to improve vaccine formulations, represent the industry's commitment to advancing healthcare solutions and boosting global access to essential treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Albumin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Albumin Market Segments Analysis

Global Albumin Market is segmented by Type, Application, Sales Channel, End-User and region. Based on Type, the market is segmented into Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin. Based on Application, the market is segmented into Therapeutics, Drug Formulation and Vaccines, Component of Media and Other Applications. Based on Sales Channel, the market is segmented into Business-To-Consumer (B2C) and Business-To-Business (B2B). Based on End-User, the market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Albumin Market

The albumin market is driven by several key factors, notably the rising demand for albumin in regenerative medicine, vaccine stabilization, and drug formulations. Its significance in contemporary biopharmaceuticals is highlighted by its applications in plasma expansion, drug delivery systems, and nanomedicine. Additionally, the increasing prevalence of chronic diseases, including conditions such as hypovolemia and liver disorders, is prompting pharmaceutical companies to innovate and develop new therapeutic drugs. This growing patient population necessitates advanced treatments, further stimulating the demand for albumin and enhancing its role as a crucial component in various medical applications and drug formulations.

Restraints in the Albumin Market

The albumin market faces significant challenges due to the intricate and costly production processes, particularly for recombinant albumin. The extensive reliance on plasma collection results in complexities surrounding purification and quality control for plasma-derived albumin. Additionally, the operational costs are heightened by fluctuations in plasma supply, stringent regulatory approval processes, and the necessity for cold-chain logistics. These factors collectively impede accessibility and affordability, particularly in developing regions, ultimately acting as major restraints on the albumin market's growth and expansion potential, affecting both manufacturers and end-users alike.

Market Trends of the Albumin Market

The albumin market is experiencing a notable shift towards sustainable production methods, with a growing emphasis on recombinant albumin. Concerns surrounding plasma sourcing, potential pathogen transmission, and supply chain vulnerabilities are driving companies to invest in genetic engineering technologies. This transition is yielding innovative alternatives, including plant-based and yeast-expressed recombinant albumin, which promise enhanced safety and environmental sustainability. As the industry pivots away from traditional plasma-derived products, these advancements not only address contamination risks but also offer cost-effective solutions that appeal to both manufacturers and consumers. This trend underscores a broader commitment to safety and sustainability in biopharmaceutical manufacturing.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Albumin Market Size by Type & CAGR (2025-2032)

• Market Overview
• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin

Global Albumin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutics
• Drug Formulation and Vaccines
• Component of Media
• Other Applications

Global Albumin Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Business-To-Consumer (B2C)
• Business-To-Business (B2B)

Global Albumin Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Research Institutes

Global Albumin Market Size & CAGR (2025-2032)

• North America (Type, Application, Sales Channel, End-User)
  • US
  • Canada
• Europe (Type, Application, Sales Channel, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Sales Channel, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Sales Channel, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Sales Channel, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novozymes A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ventria Bioscience (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albumedix Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HiMedia Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitria (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medxbio Pte Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RayBiotech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SeraCare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albumin Therapeutics, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations